Abstract: A dielectric ceramic composition contains a base material main ingredient and an accessory ingredient. The base material main ingredient includes a first base material main ingredient containing BaTiO3 and a second base material main ingredient containing (Na1-yKy)NbO3. The base material main ingredient is represented by (1-x)BaTiO3-x(Na1-yKy)NbO3, in which x and y satisfy 0.005?x?0.5 and 0.3?y?1.0, respectively.

Abstract: There is provided a dielectric ceramic composition including: a major component (a barium titanate-based base material); and a minor component, wherein in an XRD analysis of a sintered body obtained by sintering the dielectric ceramic composition, when a (110) peak of BaTiO3 is set as 1.00, a ratio of a peak of pyrochlore (RE2Ti2O7) at about 30.5 degrees with respect to the (110) peak of BaTiO3 satisfies 0.02 or less, where RE is at least one of Y, Dy, Ho, Sm, Gd, Er, La, Ce, Nd, Tb, and Pr.

Abstract: A carbon dioxide adsorbent may include a complex oxide including barium and titanium, wherein the complex oxide has a perovskite crystalline structure and is represented by the general formula BaxTiyOz, and an atomic ratio of Ba/Ti ranges from about 0.95 to about 1.7. The carbon dioxide adsorbent may be included in a carbon dioxide capture module. The carbon dioxide adsorbent may also be used in a method of separating carbon dioxide.

Abstract: There is provided a dielectric ceramic composition including: a major component (a barium titanate-based base material); and a minor component, wherein the dielectric ceramic composition is sintered to form a sintered body having a fine structure, the fine structure includes first crystal grains in which a Ca content is lower than 2.5 mol % and second crystal grains in which a Ca content is between 2.5 mol % to 13.5 mol %, and the second crystal grains have a cross-sectional area ratio of 30% to 80% on the basis of 100% of an overall cross-sectional area of the fine structure.

Abstract: There is provided a dielectric ceramic composition including a base powder, wherein the base powder includes: a first major component represented by BaTiO3, a second major component represented by (Na, K)NbO3, and a third major component represented by (Bi, Na)TiO3. The base powder is represented by xBaTiO3-y(Na, K)NbO3-z(Bi, Na)TiO3, where x+y+z=1, and x, y, and z are represented by mol, and x, y and z satisfy 0.5?x?0.97, 0.01?y?0.48, and 0.02?z?0.2, respectively. In certain embodiments, the base powder is be represented by xBaTiO3-y(Na0.5K0.5NbO3-z(Bi0.5Na0.5)TiO3.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.

Abstract: A carbon dioxide adsorbent may include a complex oxide including barium and titanium, wherein the complex oxide has a perovskite crystalline structure and is represented by the general formula BaxTiyOz, and an atomic ratio of Ba/Ti ranges from about 0.95 to about 1.7. The carbon dioxide adsorbent may be included in a carbon dioxide capture module. The carbon dioxide adsorbent may also be used in a method of separating carbon dioxide.

Abstract: The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1; fragments of the extracellular soluble domain of DLK1; mutants of the extracellular soluble domain of DLK1; a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient; and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith.

Abstract: The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.

Abstract: A method of preparing lithium titanate nanoparticles, the method including: feeding reactants including lithium and titanium into a reactor, followed by mixing the reactants in the reactor at a molecular level; and generating a crystal nucleus by chemically reacting the reactants in the reactor.

Abstract: Disclosed is a method for manufacturing a lithium transition metal phosphate. The disclosed method for manufacturing a lithium transition metal phosphate comprises the steps of: injecting reaction materials containing lithium, a transition metal, and a phosphate, into a reactor, and mixing the raw materials at the molecular level in the reactor; and allowing the reaction materials to chemically react in the reactor so as to cause nucleation.